AI Article Synopsis
- A study assessed prognostic factors for identifying Hodgkin lymphoma (HL) patients at risk of treatment resistance or relapse, focusing on CD68 expression and interim PET (iPET) results among 158 patients diagnosed between 1995 and 2011.
- Patients with low CD68 expression (≤25% positive cells) had significantly better five-year overall survival (88.4%) and progression-free survival (74.5%) than those with high expression (>25% positive cells, 63.2% and 40.7%, respectively).
- The study found a correlation between CD68 levels and iPET results, with positive iPET more common in patients with high CD68, suggesting CD68 can help better stratify patient
Article Abstract
Finding new prognostic factors to identify patients with Hodgkin lymphoma (HL) at risk of treatment resistance or relapse remains challenging in daily practice. We evaluated the relationship between CD68 expression, interim positron emission tomography (iPET) results and outcome in 158 patients with HL diagnosed from February 1995 to July 2011. Immunohistochemistry (anti-CD68) gave two groups: low with ≤25% positive cells (121 patients) and high with >25% (37 patients). Five-year overall survival was higher in the low group (88.4% vs. 63.2%, p=0.0151), as was progression-free survival (74.5% vs. 40.7%, p=0.0003). In 68 patients evaluable, iPET correlated with CD68: 13/52 patients (25%) in the low group had positive iPET as compared to 11/16 patients (68%) in the high group (p=0.0016). This study confirms the prognostic value of CD68 in HL. We found a correlation between CD68 and iPET suggesting potential for a better stratification.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/10428194.2014.917636 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!